COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

CPTAC-EDRN Joint Session

EDRN-CPTAC Joint Session at the 9th US-HUPO Annual Conference, Baltimore MD  

The National Cancer Institute (NCI)’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Early Detection Research Network (EDRN) will host a session during the 9th US-Human Proteome Organization Annual Conference entitled “Highlights from NCI Proteomic Research Programs.” The purpose is to highlight the translational nature of these programs, and present some recent work in developing new candidate targets and biomarkers for clinical use.  Please see the agenda below.

EDRN is a network of investigators committed to the discovery, development and validation of cancer biomarkers and assays for clinical use. EDRN investigators are developing biomarkers for cancer early detection, diagnosis and prognosis and conducting a multi-institutional validation studies to prove their clinical utility.

CPTAC is a comprehensive and coordinated effort of investigators to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows.  CPTAC is to identify proteins that derive from alterations in cancer genomes (such as tumors from NCI's Cancer Genome Atlas (TCGA)) and related biological processes, and provide all data with accompanying assays and protocols to the public.

Monday March 11, 2013

Moderators:    Jacob Kagan, M.Sc., Ph.D. and Mehdi Mesri, MMedSc., Ph.D.  The National Cancer Institute

Introduction: NCI Proteomics

5:30 PM – 5:35 PM

The Early Detection Research Network: Proteomics Based Biomarkers
Sudhir Srivastava Ph.D., M.P.H. NCI

5:35 PM – 5:40 PM

Clinical Proteomic Tumor Analysis Consortium
Henry Rodriguez, Ph.D. NCI
Proteomic Research Highlights: 5:40 PM – 6:00 PM

The Pathway from Biomarkers Discovery to FDA approval
Daniel W. Chan, Ph.D., Johns Hopkins University

6:00 PM – 6:20 PM

Mass-Spectrometry-Based Tumor Tissue Analysis
Daniel C. Liebler, Ph.D., Vanderbilt University Medical Center

6:20 PM – 6:40 PM

Targeted SRM Quantification at the PNNL EDRN BRL: Toward Clinical Utility
David G Camp II, Ph.D. Pacific Northwest National Laboratory

6:40 PM – 6:50 PM

Question and Answer Session

The joint session begins promptly on Monday March 11th at 5:30 PM at Baltimore Hilton, Baltimore, MD.  Room TBD. To learn more about CPTAC and EDRN recent accomplishments, be sure not to miss this event.

We look forward to your attendance.

Thank you

Jacob Kagan, M.Sc., Ph.D.
The Early Detection Research Network

Mehdi Mesri, MMedSc., Ph.D.
Office of Cancer Clinical Proteomics Research